Literature DB >> 16914408

The mystery of motor asymmetry in Parkinson's disease.

Ruth Djaldetti1, Ilan Ziv, Eldad Melamed.   

Abstract

The motor symptoms of Parkinson's disease are predominantly due to progressive degeneration of nigral dopaminergic neurons. In most cases there is a substantial asymmetry of clinical symptoms from disease onset, which occurs in sporadic and in hereditary forms of the disease. However, the mechanism of such unilaterality of symptom appearance is not understood. There is only sparse information about whether symptom-side predominance is genetically coded and determined years before symptom onset, or whether it is acquired and related to side differences in vulnerability of the degenerating neurons. In this Personal View we review data for unilaterality of symptoms at different disease stages. We also discuss several pathological, genetic, environmental, and toxic possibilities for explaining the mechanism of side predominance.

Entities:  

Mesh:

Year:  2006        PMID: 16914408     DOI: 10.1016/S1474-4422(06)70549-X

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  94 in total

1.  Handedness and motor symptom asymmetry in Parkinson's disease.

Authors:  Matthew J Barrett; Scott A Wylie; Madaline B Harrison; G Frederick Wooten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-09-22       Impact factor: 10.154

Review 2.  Cognitive differences between patients with left-sided and right-sided Parkinson's disease. A review.

Authors:  Nele Verreyt; Gudrun M S Nys; Patrick Santens; Guy Vingerhoets
Journal:  Neuropsychol Rev       Date:  2011-09-29       Impact factor: 7.444

3.  Detecting asymmetries in balance control with system identification: first experimental results from Parkinson patients.

Authors:  H van der Kooij; E H F van Asseldonk; J Geelen; J P P van Vugt; B R Bloem
Journal:  J Neural Transm (Vienna)       Date:  2007-08-16       Impact factor: 3.575

4.  Progression of postural changes in Parkinson's disease: quantitative assessment.

Authors:  Alexander Khlebtovsky; Ruth Djaldetti; Yaniv Rodity; Ofir Keret; Gloria Tsvetov; Ilana Slutzcki-Shraga; Felix Benninger
Journal:  J Neurol       Date:  2017-02-02       Impact factor: 4.849

5.  Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks.

Authors:  Karina Stavitsky; Patrick McNamara; Raymon Durso; Erica Harris; Sanford Auerbach; Alice Cronin-Golomb
Journal:  Cogn Behav Neurol       Date:  2008-09       Impact factor: 1.600

6.  Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease.

Authors:  Jian Wang; YiLong Ma; ZheMin Huang; BoMin Sun; YiHui Guan; ChuanTao Zuo
Journal:  J Neurol       Date:  2009-08-07       Impact factor: 4.849

7.  Linguistic correlates of asymmetric motor symptom severity in Parkinson's Disease.

Authors:  Thomas Holtgraves; Patrick McNamara; Kevin Cappaert; Raymond Durso
Journal:  Brain Cogn       Date:  2009-09-13       Impact factor: 2.310

8.  Reply: Does dominant pedunculopontine nucleus exist? Probably not.

Authors:  Brett W Fling; John G Nutt; Fay B Horak
Journal:  Brain       Date:  2014-11-02       Impact factor: 13.501

9.  Gray Matter Abnormalities in Idiopathic Parkinson's Disease: Evaluation by Diffusional Kurtosis Imaging and Neurite Orientation Dispersion and Density Imaging.

Authors:  Koji Kamagata; Andrew Zalesky; Taku Hatano; Ryo Ueda; Maria Angelique Di Biase; Ayami Okuzumi; Keigo Shimoji; Masaaki Hori; Karen Caeyenberghs; Christos Pantelis; Nobutaka Hattori; Shigeki Aoki
Journal:  Hum Brain Mapp       Date:  2017-05-04       Impact factor: 5.038

10.  Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder.

Authors:  Timothy M Ellmore; Richard J Castriotta; Katie L Hendley; Brian M Aalbers; Erin Furr-Stimming; Ashley J Hood; Jessika Suescun; Michelle R Beurlot; Roy T Hendley; Mya C Schiess
Journal:  Sleep       Date:  2013-12-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.